News

23 May 2017	Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signi… Read more
23 May 2017	Holding(s) in Company Read more
18 May 2017	Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option LONDON, May 18, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signif… Read more
16 May 2017	Partial Exercise of Over-Allotment Option THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Read more
9 May 2017	Holding(s) in Company Read more
8 May 2017	Holding(s) in Company Read more
5 May 2017	Holding(s) in Company Read more
5 May 2017	Holding(s) in Company Read more
5 May 2017	Holding(s) in Company Read more
3 May 2017	Holding(s) in Company Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Verona Pharma plc

Site map